LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling
2011

LY6K as a Target in Bladder Cancer

Sample size: 128 publication Evidence: high

Author Information

Author(s): Matsuda R, Enokida H, Chiyomaru T, Kikkawa N, Sugimoto T, Kawakami K, Tatarano S, Yoshino H, Toki K, Uchida Y, Kawahara K, Nishiyama K, Seki N, Nakagawa M

Primary Institution: Kagoshima University

Hypothesis

The study aims to identify a novel molecular target based on chromosomal alterations and gene expression analyses in bladder cancer.

Conclusion

The oncogenic LY6K gene located at 8q24.3 may play a significant role in the development of bladder cancer.

Supporting Evidence

  • LY6K mRNA expression was significantly higher in 91 bladder cancer samples than in 37 normal bladder epithelium samples.
  • High LY6K expression was validated by fluorescence in situ hybridization due to gene amplification.
  • Knockdown of LY6K resulted in significant decreases in cell growth, migration, and invasion in bladder cancer cell lines.

Takeaway

Researchers found that a gene called LY6K is more active in bladder cancer cells than in normal cells, which might help in developing new treatments.

Methodology

The study used high-resolution array-comparative genomic hybridization and real-time reverse transcription PCR to analyze gene expression in bladder cancer cell lines and clinical samples.

Limitations

The study did not find a relationship between LY6K expression and clinicopathological parameters.

Participant Demographics

91 bladder cancer patients and 37 normal bladder epithelium samples were analyzed.

Statistical Information

P-Value

p<0.0001

Confidence Interval

95% CI 12.4–26.8

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1038/sj.bjc.6605990

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication